Bontril (Phendimetrazine Tartrate) - Indications and Dosage

INDICATIONS

Phendimetrazine tartrate is indicated in the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction. The limited usefulness of agents of this class (see ACTIONS) should be measured against possible risk factors inherent in their use such as those described below.

DOSAGE AND ADMINISTRATION

One Slow-Release Capsule (105 mg) in the morning, taken 30-60 minutes before the morning meal.

Phendimetrazine Tartrate is not recommended for use in children under twelve years of age.

HOW SUPPLIED

Bontril Slow Release Capsules (phendimetrazine tartrate 105 mg) is available as opaque green and clear yellow capsules, imprinted with “VALEANT” and “BONTRIL 105”. Phendimetrazine Slow-Release Capsules are available in bottles of 100 (NDC #0187-0498-01) and 1000 (NDC 0187-0498-02).

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

Manufactured for
Valeant Pharmaceuticals International
3300 Hyland Ave.
Costa Mesa, CA 92626 U.S.A.

Manufactured by
Mallinckrodt Inc.
Hobart, NY 13788

Printed with food grade ink.

Rev. 9/04
Part No. L2BB02